4D Molecular Therapeutics
FDMT4D Molecular Therapeutics is a late-stage biotechnology company focused on developing targeted genetic medicines using its proprietary Therapeutic Vector Evolution (TVE) platform.
Earnings
Next report
Nov 10, 2026 (In 1 week)Valuation & ratios
Segments
Competitors
By market cap
By revenue growth
By net margin
Profile
4D Molecular Therapeutics is a late-stage biotechnology company focused on developing targeted genetic medicines using its proprietary Therapeutic Vector Evolution (TVE) platform. The company utilizes directed evolution in non-human primates to create customized adeno-associated virus (AAV) vectors designed to overcome the limitations of conventional gene therapies. Its primary value proposition lies in delivering durable, disease-modifying treatments for retinal and respiratory diseases through routine routes of administration.
A late-stage clinical player with a proprietary directed-evolution platform that differentiates its AAV vectors from conventional and mouse-evolved alternatives.
FAQ
- What is 4D Molecular Therapeutics's market cap?
- 4D Molecular Therapeutics (FDMT) has a market capitalization of $706.0M and trades on NASDAQ.
- What is 4D Molecular Therapeutics's revenue and profitability?
- 4D Molecular Therapeutics generated $92.0M in trailing twelve-month revenue, representing a net margin of -174314.2%. The latest reported period is Q2 2026.
- Who are 4D Molecular Therapeutics's competitors?
- 4D Molecular Therapeutics's key competitors include REGENXBIO Inc., Regeneron Pharmaceuticals Inc., Kalaris Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does 4D Molecular Therapeutics partner with?
- 4D Molecular Therapeutics's notable partners include Otsuka Pharmaceutical Co., Ltd., Cystic Fibrosis Foundation, California Institute for Regenerative Medicine, and others.
- Where is 4D Molecular Therapeutics headquartered?
- 4D Molecular Therapeutics is headquartered in United States of America and employs approximately 171 people. It has been publicly traded since 2020.
